Phase I trial of the SPf66 malaria vaccine in a malaria-experienced population in Southeast Asia

American Journal of Tropical Medicine and Hygiene

Volumn 56, Issue 5, 1997, Pages 526-532

  Nosten, Francois ^a   Luxemburger, Christine ^a   Kyle, Dennis E ^b   Gordon, Daniel M ^b   Ballou, W Ripley ^b   Sadoff, Jerald C ^b   Brockman, Alan ^a   Permpanich, Barynen ^c   Chongsuphajaisiddhi, Tan ^d   Heppner, D Gray ^c,e  

^a SHOKLO MALARIA RESEARCH UNIT   (Thailand)

^b WALTER REED ARMY INSTITUTE OF RESEARCH   (United States)

^c ARMED FORCES RESEARCH INSTITUTE OF MEDICAL SCIENCES   (Thailand)

^d MAHIDOL UNIVERSITY   (Thailand)

^e AFRIMS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM; MALARIA VACCINE;

ADOLESCENT; ADULT; ANTIMALARIAL ACTIVITY; ARTICLE; CHILD; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHEMA; FEMALE; FOLLOW UP; GOOD MANUFACTURING PRACTICE; HUMAN; HUMAN EXPERIMENT; IMMUNOGENICITY; INJECTION PAIN; MALARIA CONTROL; MALARIA FALCIPARUM; MALE; NORMAL HUMAN; PHASE 1 CLINICAL TRIAL; SEROCONVERSION; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME; VACCINE PRODUCTION;

EID: 0030955715     PISSN: 00029637     EISSN: None     Source Type: Journal    
DOI: 10.4269/ajtmh.1997.56.526     Document Type: Article

References (17)

1. Sturchler D, 1989. How much malaria is there worldwide? Parasitol Today 5: 39-40.
2. Luxemburger C, Thwai KL, White NJ, Webster HK, Kyle DE, Maelankiri L, Chongsuphajaisiddhi T, Nosten F, 1996. The epidemiology of malaria in a Karen population on the Thai-Burmese border. Trans R Soc Trop Med Hyg 90: 105-111.
3. Patarroyo ME, Romero P, Torres ML, Clavijo P, Moreno A, Martinez A, Rodriquez R, Guzman F, Cabezas E, 1987. Induction of protective immunity against experimental infection with malaria using synthetic peptides. Nature 328: 629-632.
4. Patarroyo ME, Amador R, Clavijo P, Moreno A, Guzman F, Romero P, Tascon R, Franco A, Murillo LA, Ponton G, Trujillo G, 1988. A synthetic vaccine protects humans against challenge with asexual blood stages of Plasmodium falciparum malaria. Nature 332: 158-161.
5. Valero MV, Amador LR, Galindo C, Figueroa J, Bello MS, Murrillo LA, Mora AL, Patarroyo G, Rocha CL, Rojas M, Aponte JJ, Sarmiento LE, Lozada DM, Coronell CG, Ortega NM, Rosas JE, Alonso PL, Patarroyo ME, 1993. Vaccination with SPf66, a chemically synthesised vaccine, against Plasmodium falciparum in Colombia. Lancet 341: 705-710.
6. Alonso PL, Smith T, Armstrong Schellenberg JRM, Masanja H, Mwankusye S, Urassa H, Bastos de Azevedo I, Chongela J, Kobero S, Menendez C, Hurt N, Thomas MC, Lyimo E, Weiss NA, Hayes R, Kitua AY, Lopez MC, Kilama WL, Teuscher T, Tanner M, 1994. Randomised trial of efficacy of SPf66 vaccine against Plasmodium falciparum malaria in children in southern Tanzania. Lancet 344: 1175-1181.
7. D'Alessandro U, Leach A, Drakeley CJ, Bennet S, Olaleye BO, Fegan GW, Jawara M, Langerock P, George MO, Targett GAT, Greenwood BM, 1995. Efficacy trial of malaria vaccine SPf66 in Gambian infants. Lancet 346: 462-467.
8. Gordon DM, Duffy PE, Heppner DG, Lyon JA, Williams JS, Scheumann D, Farley L, Stacey D, Haynes JD, Sadoff JC, Ballou WR, 1996. Phase I safety and immunogenicity testing of clinical lots of the synthetic Plasmodium falciparum vaccine SPf66 produced under good manufacturing procedure conditions in the United States. Am J Trop Med Hyg 55: 63-68.
9. Leach A, Drakeley CJ, D'Alessandro U, Fegan GW, Bennett S, Ballou WR, Targett GAT, Greenwood BM, 1995. A pilot safety and immunogenicity study of the malaria vaccine SPf66 in Gambian infants. Parasite Immunol 17: 441-444.
10. Ballou WR, Blood J, Chongsuphajaisiddhi T, Gordon DM, Heppner DG, Kyle DE, Luxemburger C, Nosten F, Sadoff JC, Singhasivanon P, White NJ, Webster HK, Wittes J, Wongsrichanalai C, 1995. Field trials of an asexual blood stage malaria vaccine: studies of the synthetic peptide polymer SPf66 in Thailand and the analytic plan for a Phase IIb efficacy study. Parasitology 110: S25-S36.
11. Nosten F, Luxemburger C, Kyle DE, Ballou WR, Wittes J, Wah E, Chongsuphajaisiddhi T, Gordon DM, White NJ, Sadoff JC, Heppner DG, 1996. Randomised double-blind placebo-controlled trial of SPf66 malaria vaccine in children in north-western Thailand. Lancet 348: 701-708.
12. Amador R, Moreno A, Murillo LA, Sierra O, Saavedra D, Rojas M, Mora AL, Rocha CL, Alvarado F, Falla JC, Orozco M, Coronell C, Ortega N, Molano A, Velasquez JF, Valero MV, Franco L, Guzman F, Salazar LM, Espejo F, Mora E, Farfan R, Zapata N, Rosas J, Calvo JC, Castro J, Quinones T, Nunez F, Patarroyo ME, 1992. Safety and immunogenicity of the synthetic malaria vaccine SPf66 in a large field trial. J Infect Dis 166: 139-144.
13. Teuscher T, Armstrong Schellenberg JRM, Bastos de Azevedo I, Hurt N, Smith T, Hayes R, Masanja H, Silva Y, Lopez MC, Kitua A, Kilama W, Tanner M, Alonso PL, 1994. SPf66, a chemically synthesized subunit malaria vaccine, is safe and immunogenic in Tanzanians exposed to intense malaria transmission. Vaccine 12: 328-336.
14. Noya O, Berti YG, Alarcon de Noya B, Borges R, Zerpa N, Urbaez JD, Madonna A, Garrido E, Auxiliadora Jimenez M, Borges RE, Garcia P, Reyes I, Prieto W, Colmenares C, Pabon R, Barraez T, de Caceres LG, Godoy N, Sifontes R, 1994. A population-based clinical trial with the SPf66 synthetic Plasmodium falciparum malaria vaccine in Venezuela. J Infect Dis 170: 396-402.
15. Sempertegui F, Estrella B, Moscoso J, Piedrahita L, Hernandez D, Gaybor J, Naranjo P, Mancero O, Arias S, Bernal R, Cordova ME, Suarez J, Zicker F, 1994. Safety, immunogenicity and protective effect of the SPf66 malaria synthetic vaccine against Plasmodium falciparum infection in a randomized double-blind placebo-controlled field trial in an endemic area of Ecuador. Vaccine 12: 337-342.
16. Salcedo M, Barreto L, Rojas M, Moya R, Cote J, Patarroyo ME, 1991. Studies on the humoral immune response to a synthetic-vaccine against Plasmodium falciparum malaria. Clin Exp Immunol 84: 122-128.
17. Patarroyo G, Franco L, Amador R, Murillo LA, Rocha CL, Rojas M, Patarroyo ME, 1992. Study of the safety and immunogenicity of the synthetic malaria SPf66 vaccine in children aged 1-14 years. Vaccine 10: 175-178.